Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Clinical pharmacology, creating current and future success in drug development.

Rogge MC, Dresser M, Fossler M, Heald D, Stoch SA, Vanevski KM, Bello A.

J Clin Pharmacol. 2015 Nov;55(11):1193-7. doi: 10.1002/jcph.547. Epub 2015 Jul 14. No abstract available.

PMID:
25998173
2.

Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation.

Khera PK, Smith EP, Lindsell CJ, Rogge MC, Haggerty S, Wagner DA, Palascak MB, Mehta S, Hibbert JM, Joiner CH, Franco RS, Cohen RM.

Am J Hematol. 2015 Jan;90(1):50-55. doi: 10.1002/ajh.23866.

3.

Interferon beta assessment in non-Chinese and Chinese subjects: pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent.

Rogge MC, Liu Y, Galluppi GR.

J Clin Pharmacol. 2014 Oct;54(10):1153-61. doi: 10.1002/jcph.311. Epub 2014 Apr 23.

PMID:
24737408
4.

Interaction-induced spin polarization in quantum dots.

Rogge MC, Räsänen E, Haug RJ.

Phys Rev Lett. 2010 Jul 23;105(4):046802. Epub 2010 Jul 20.

PMID:
20867873
5.

Multiple transitions of the spin configuration in quantum dots.

Rogge MC, Fühner C, Haug RJ.

Phys Rev Lett. 2006 Oct 27;97(17):176801. Epub 2006 Oct 24.

PMID:
17155491
6.

Preclinical safety of recombinant human thrombin.

Heffernan JK, Ponce RA, Zuckerman LA, Volpone JP, Visich J, Giste EE, Jenkins N, Boster D, Pederson S, Knitter G, Palmer T, Wills M, Early RJ, Rogge MC.

Regul Toxicol Pharmacol. 2007 Feb;47(1):48-58. Epub 2006 Sep 12.

PMID:
16971028
7.

Bioavailability and relative tissue distribution of [125I]-recombinant human thrombin following intravenous or subcutaneous administration to non-human primates.

Visich JE, Byrnes-Blake KA, Lewis KB, Meengs B, Rogge MC.

J Thromb Haemost. 2006 Sep;4(9):1962-8. Epub 2006 Jun 22.

8.

Probing a Kondo-correlated quantum dot with spin spectroscopy.

Kupidura D, Rogge MC, Reinwald M, Wegscheider W, Haug RJ.

Phys Rev Lett. 2006 Feb 3;96(4):046802. Epub 2006 Feb 1.

PMID:
16486867
9.

Preclinical safety and pharmacokinetics of recombinant human factor XIII.

Ponce RA, Visich JE, Heffernan JK, Lewis KB, Pederson S, Lebel E, Andrews-Jones L, Elliott G, Palmer TE, Rogge MC.

Toxicol Pathol. 2005;33(4):495-506.

PMID:
16036868
10.

Enbrel (etanercept).

Foerder CA, Rogge MC.

Dev Biol (Basel). 2002;109:99-102. No abstract available.

PMID:
12434918
11.

Absence of a pharmacokinetic interaction between digoxin and levofloxacin.

Chien SC, Rogge MC, Williams RR, Natarajan J, Wong F, Chow AT.

J Clin Pharm Ther. 2002 Feb;27(1):7-12. Erratum in: J Clin Pharm Ther 2002 Jun;27(3):231.

PMID:
11846857
12.

Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.

Galluppi GR, Rogge MC, Roskos LK, Lesko LJ, Green MD, Feigal DW Jr, Peck CC.

Clin Pharmacol Ther. 2001 Jun;69(6):387-99. No abstract available.

PMID:
11406736
13.

Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration.

Rogge MC, Simonian NA, Jones WE.

Eur J Neurol. 1999 May;6(3):375-7. No abstract available.

PMID:
10210923
14.

Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.

Gobburu JV, Tenhoor C, Rogge MC, Frazier DE Jr, Thomas D, Benjamin C, Hess DM, Jusko WJ.

J Pharmacol Exp Ther. 1998 Aug;286(2):925-30.

PMID:
9694951
15.

Impaired bioavailability of interferon beta-1a when administered intramuscularly by needle-free injection.

Rogge MC, Charenkavanich S, DiBiase M, Jones W, Knox SJ, Alam JJ.

Drug Deliv. 1998;5(4):275-80. doi: 10.3109/10717549809065758.

PMID:
19569995
16.

Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.

Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, Williams RR, Fowler CL, Cheung WK, Chow AT.

Antimicrob Agents Chemother. 1997 Oct;41(10):2256-60.

17.

Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.

Chien SC, Chow AT, Rogge MC, Williams RR, Hendrix CW.

Antimicrob Agents Chemother. 1997 Aug;41(8):1765-9.

18.

Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.

Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK.

Antimicrob Agents Chemother. 1997 Jul;41(7):1562-5.

19.

Pharmacokinetics and distribution in tissue of FK-037, a new parenteral cephalosporin.

Wise R, Andrews JM, O'Neill P, Jolley A, Fowler C, Rogge MC.

Antimicrob Agents Chemother. 1994 Oct;38(10):2369-72.

20.

Activity of levofloxacin in a murine model of tuberculosis.

Klemens SP, Sharpe CA, Rogge MC, Cynamon MH.

Antimicrob Agents Chemother. 1994 Jul;38(7):1476-9.

21.
22.
23.

Effect of food and a monoglyceride emulsion formulation on danazol bioavailability.

Charman WN, Rogge MC, Boddy AW, Berger BM.

J Clin Pharmacol. 1993 Apr;33(4):381-6.

PMID:
8473554
24.

Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses.

Lettieri JT, Rogge MC, Kaiser L, Echols RM, Heller AH.

Antimicrob Agents Chemother. 1992 May;36(5):993-6.

25.

Self-emulsifying drug delivery systems: formulation and biopharmaceutic evaluation of an investigational lipophilic compound.

Charman SA, Charman WN, Rogge MC, Wilson TD, Dutko FJ, Pouton CW.

Pharm Res. 1992 Jan;9(1):87-93.

PMID:
1589415
26.

In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Woods MG, Diana GD, Rogge MC, Otto MJ, Dutko FJ, McKinlay MA.

Antimicrob Agents Chemother. 1989 Dec;33(12):2069-74.

27.

The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin.

Rogge MC, Solomon WR, Sedman AJ, Welling PG, Koup JR, Wagner JG.

Clin Pharmacol Ther. 1989 Oct;46(4):420-8.

28.

The theophylline-enoxacin interaction: I. Effect of enoxacin dose size on theophylline disposition.

Rogge MC, Solomon WR, Sedman AJ, Welling PG, Toothaker RD, Wagner JG.

Clin Pharmacol Ther. 1988 Nov;44(5):579-87.

29.

Single dose and steady-state pharmacokinetics of adinazolam after oral administration to man.

Wagner JG, Rogge MC, Natale RB, Albert KS, Szpunar GJ.

Biopharm Drug Dispos. 1987 Sep-Oct;8(5):405-25.

PMID:
3663878
30.

Absorption of theophylline from two sustained release formulations.

Selen A, Johnson CA, Rogge MC, Craig WA, Welling PG.

Biopharm Drug Dispos. 1985 Apr-Jun;6(2):217-21. No abstract available.

PMID:
4005398
31.

A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures.

Welling PG, Selen A, Pearson JG, Kwok F, Rogge MC, Ifan A, Marrero D, Craig WA, Johnson CA.

Biopharm Drug Dispos. 1985 Apr-Jun;6(2):147-57.

PMID:
4005394
32.

Vancomycin disposition during continuous ambulatory peritoneal dialysis: a pharmacokinetic analysis of peritoneal drug transport.

Rogge MC, Johnson CA, Zimmerman SW, Welling PG.

Antimicrob Agents Chemother. 1985 Apr;27(4):578-82.

33.

Bioavailability of hydrocortisone from commercial 20-mg tablets.

Patel RB, Rogge MC, Selen A, Goehl TJ, Shah VP, Prasad VK, Welling PG.

J Pharm Sci. 1984 Jul;73(7):964-6.

PMID:
6470962
34.

Bioavailability of hydrochlorothiazide from tablets and suspensions.

Patel RB, Patel UR, Rogge MC, Shah VP, Prasad VK, Selen A, Welling PG.

J Pharm Sci. 1984 Mar;73(3):359-61.

PMID:
6716243

Supplemental Content

Loading ...
Support Center